High positivity of anti-CCP antibodies in patients with Down syndrome

Clinical Rheumatology

Volumn 26, Issue 12, 2007, Pages 2031-2035

  Nisihara, Renato M ^a,c   Skare, Thelma L ^b   Silva, Marília B G ^b   Messias Reason, Iara T ^a   Oliveira, Nanci P ^a   Fiedler, Patricia T ^a   Utiyama, Shirley R R ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^c NONE   (Brazil)

Author keywords

Anti CCP antibodies; Down syndrome; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR;

EID: 36248957581     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0606-1     Document Type: Article

References (27)

1. National Birth Defects Prevention Network (2003) Birth defects surveillance data from selected states, 1996-2000. Birth Defects Res A Clin Mol Teratol 67:729-818
2. Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down's syndrome 1980-96. Paediatr Perinat Epidemiol 14:163-171
3. Pueschel SM, Anneren G, Durlach R et al (1995) Guidelines for optimal care of persons with Down syndrome. Acta Paediatr 84:823-827
4. Ugazio AG, Maccario R, Notarangelo LD, Burgio GR (1990) Immunology of Down syndrome: A review. Am J Med Genet 7:202-212
5. Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2005) Celiac disease in children and adolescents with Down syndrome. J Pediatr 81(5):373-376
6. Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2006) Alterations of TSH in Down syndrome patients: A hard interpretation. Rev Med Lab 46:333-337
7. Anwar AJ, Walker JD, Frier BM (1998) Type-1 diabetes mellitus and Down's syndrome: Prevalence, management and diabetic complications. Diabet Med 15:160-163
8. Goldacre MJ, Wotton CJ, Seagroatt V, Yeats D (2004) Cancers and immune related diseases associated with Down's syndrome: A record linkage study. Arch Dis Child 89:1014-1017
9. Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology 41:1191-1193
10. Yancey C, Zmijewski C, Athreya BH, Doughty RA (1984) Arthropathy of Downs' syndrome. Arthritis Rheum 27:929-934
11. Olson JC, Bender JC, Levinson JE, Oestreich A, Loveli D (1990) Arthropathy of Down syndrome. Pediatrics 86:931-936
12. Kinnel HG (1984) Arthritis in Down's syndrome. Br J Radiol 54:1167
13. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677-680
14. Grahane R (1998) Hypermobility syndrome. In: Kilpell JH, Fieppe PA (eds) Rheumatology, 2nd edn. Mosby, London, S8-51.1-51.6
15. Cuadrado E, Barrena MJ (1996) Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 78:209-214
16. Jansen AL, van den Horst-Bruisma IE, van Shaardenburg D, Van den Stad RJ, de Konig MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2074-2076
17. Hingh YC, Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, Vries E (2005) Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147:744-747
18. Franciotta D, Verri A, Zardini E, Andreoni L, Amici M, Moratti R, Nespoli L (2006) Interferon γ and interleukin-4 producing T cells in Down's syndrome. Neurosci Lett 395:67-70
19. Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:303-308
20. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47(3):171-176
21. Ferraro AS, Newkirk MM (1993) Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 92:425-431
22. Newkirk MM (2002) Rheumatoid factors: Host resistance or autoimmunity? Clin Immunol 104:1-13
23. Posnett DN, Edinger J (1997) When do microbes stimulate rheumatoid factor? J Exp Med 185:1721-1723
24. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647-651
25. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733-741
26. Ates A, Karaaslan Y, Aksaray S (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 26(4):499-504 (May 3)
27. Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. Clin Rheumatol 26(2):201-204 (Mar 30)